Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRG | P62508 | 2/20 | 0.44 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | GCGR | P47871 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NPY1R | P25929 | 1/20 | 0.35 |
| ▸ | NPY2R | P49146 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1484325 | 1.00 | ESRRG (0.44) | ESRRGAGTR1KDM4EMAPTNPC1 | |
| SCHEMBL13720945 | 1.00 | ESRRG (0.44) | ESRRGAGTR1KDM4EMAPTNPC1 | |
| SCHEMBL1483807 | 0.91 | NR1H4 (0.46) | ESRRGAGTR1KDM4EMAPTNPC1 | |
| SCHEMBL13720458 | 0.91 | NR1H4 (0.46) | ESRRGAGTR1KDM4EMAPTNPC1 | |
| SCHEMBL1483809 | 0.91 | NR1H4 (0.46) | ESRRGAGTR1KDM4EMAPTNPC1 | |
| SCHEMBL1483415 | 0.89 | ESRRG (0.44) | ESRRGAGTR1KDM4EMAPTNPC1 | |
| SCHEMBL13720580 | 0.89 | ESRRG (0.44) | ESRRGAGTR1KDM4EMAPTNPC1 | |
| SCHEMBL13720835 | 0.89 | ESRRG (0.44) | ESRRGAGTR1KDM4EMAPTNPC1 | |
| SCHEMBL1483413 | 0.89 | ESRRG (0.44) | ESRRGAGTR1KDM4EMAPTNPC1 | |
| SCHEMBL1483843 | 0.89 | ESRRG (0.44) | ESRRGAGTR1KDM4EMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1636192-B9 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL IND LTD (JP) | 2015-07-01 | — | — | EP | disclosed |
| US-20140051857-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2014-02-20 | — | — | US | disclosed |
| EP-1636192-B1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL IND LTD (JP) | 2014-01-15 | — | — | EP | disclosed |
| US-20130012708-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2013-01-10 | — | — | US | disclosed |
| US-8318796-B2 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| CN-101386596-B | 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators | NISSAN CHEMICAL IND LTD | 2011-10-26 | — | — | CN | disclosed |
| US-20110077290-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-7576115-B2 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| CN-101386596-A | 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators | NISSAN CHEMICAL IND LTD (JP) | 2009-03-18 | — | — | CN | disclosed |
| CN-100443472-C | 3-alkylidenehydrazino substituted heteroaryl compound and medicine containing the same | NISSAN CHEMICAL IND LTD (JP) | 2008-12-17 | — | — | CN | disclosed |
| US-7351841-B2 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-04-01 | — | — | US | disclosed |
| US-20080027068-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
| CN-1798739-A | 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators | NISSAN CHEMICAL IND LTD (JP) | 2006-07-05 | — | — | CN | disclosed |
| US-20060094694-A1 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077290-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | ESRRG 121/4885AGTR1 443/4885KDM4E 4480/4885 |
| US-20060094694-A1 | Heterocyclic compounds and thrombopoietin receptor activators | NR2C2, ROR1, NR0B2 | ESRRG 131/4885AGTR1 397/4885KDM4E 4422/4885 |
| US-20080027068-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | ESRRG 123/4885AGTR1 441/4885KDM4E 4486/4885 |
| US-20140051857-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | ESRRG 121/4885AGTR1 443/4885KDM4E 4480/4885 |
| US-20130012708-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | ESRRG 121/4885AGTR1 443/4885KDM4E 4480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.